Oct 19, 2010, 11:27 ET from CRH Medical Corporation

SAN ANTONIO, Oct. 19 /PRNewswire/ - CRH Medical Corporation (CRM:TSX-V, CRMMF: OTCQX) announced today that a poster was presented at the American College of Gastroenterology conference in San Antonio, Texas. The poster documents eight years of clinical experience utilizing the CRH O'Regan System™ for the treatment of symptomatic hemorrhoids. The study, believed to be the largest of its kind, followed 6,690 patients who had their hemorrhoids treated using the CRH O'Regan System™.

The study confirms the CRH O'Regan System TM  is safe, effective and painless with a favorably low complication profile. The study reports a banding complication rate of 0.2% based on 20,286 banding procedures. The study also reports superior long term results obtained by treating patients suffering from symptomatic hemorrhoids with the CRH O'Regan System TM ; The data shows 87% of patients experienced complete relief of hemorrhoids, 5% developed partial recurrence and 8% had a full recurrence over a mean follow up period of 42 months. Inadequate daily fiber intake was found to be associated with the hemorrhoid recurrence rates. 

Commenting on the study, Edward Wright CEO of CRH Medical said "The outcome of this extensive study is further proof of the patient care advantages afforded by our technology ". Wright continued "I am confident that this study will be meaningful when physicians are deciding upon the most effective treatment for their patients. The data also closely mimics the experience we've witnessed at our own clinics and with our Physician partners, thereby illustrating the transferability of the technology and robustness of our treatment protocols."

About CRH Medical Corporation:

CRH Medical Corporation is a value added resource to the Gastroenterologist community, providing the CRH O'Regan System™, as well as delivering related, clinical, marketing and operational support directly to its partner physicians. CRH utilizes its web based platform to connect doctors with patients as well as educating its ever increasing install base of physicians.  CRH's single use, disposable, hemorrhoid technology is safe and highly effective in treating hemorrhoid grades I - IV.  The Company's goal is to establish the CRH O'Regan System™ as the standard for hemorrhoid treatment.

The information in this news release contains so-called "forward-looking" statements. These include statements regarding CRH Medical's expectations and plans relating to its business and statements about CRH Medical's expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "CRH Medical believes", "management believes", and similar language. All forward-looking statements are based on CRH Medical's current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) we may need to raise additional capital to fund future operations; (ii) the policies of health insurance carriers in the United States may affect the amount of revenue the Company receives; (iii) the Company may not successfully market its products; (iv) changes in United States federal or state laws, rules, and regulations, including those governing the corporate practice of medicine, and fee splitting; (v) changes in the United States Anti-Kickback Statute and Stark Law and/or similar state laws, rules, and regulations; (vi) if we are unable to manage growth, we may be unable to achieve our expansion strategy: (vii) our senior management has been key to our growth, and we may be adversely affected if we lose any member of our senior management; (viii) economic dependence on suppliers and our contract manufacturer; (ix) changes in the industry and the economy may affect the Company's business; * evolving regulation of corporate governance and public disclosure may result in additional corporate expenses; (xi) we may not be able to attract Gastroenterologists and other licensed providers to purchase and use the CRH O'Regan System; (xii) we may be subject to competition and technological risk which may impact the price and amount of product we can sell; (xiii) we may not be able to retain sufficient qualified physicians to operate our Centers; (xiv) we may be subject to product liability and medical malpractice claims, which may adversely affect our operations; (xv) our business may be impacted by health care reform in the United States; and (xvi) we may not have the expertise required to expand internationally. CRH Medical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE CRH Medical Corporation